[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369913-105":59,"doc-detail-369913-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-computational-immunology-applied-to-identify-and-characterize-cd8-t-cell-neoepitopes-of-shared-kras-neoantigen-oncogenic-driver-hotspot-mutations","Integrative Computational Immunology Applied to Identify and Characterize CD8+ T-cell Neoepitopes of Shared KRAS Neoantigen Oncogenic Driver Hotspot Mutations","","Integrative computational immunology is used to identify and characterize potential cytotoxic CD8+ T-cell neoepitopes derived from KRAS oncogenic hotspot mutations. Neoepitopes were curated from NEPdb and evaluated with immunoinformatic parameters including IC50 values, differential agretopicity, mutation positions, and immunogenicity. Sequences carrying G12A, G12C, G12D, G12S, G12V, G12R, G13D, and A59T substitutions were analyzed, with NetMHCPan4.1 supporting binding predictions. Safety profiling and population coverage were assessed, then top candidates were docked to estimate KD and ΔGbind. Twenty-one candidate neoepitopes were recommended.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-computational-immunology-applied-to-identify-and-characterize-cd8-t-cell-neoepitopes-of-shared-kras-neoantigen-oncogenic-driver-hotspot-mutations/369913/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-computational-immunology-applied-to-identify-and-characterize-cd8-t-cell-neoepitopes-of-shared-kras-neoantigen-oncogenic-driver-hotspot-mutations/369913.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the study?","Question",{"text":112,"@type":113},"To identify and characterize potential cytotoxic CD8+ T-cell neoepitopes generated from shared KRAS neoantigen oncogenic driver hotspot mutations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which database and tools were used to evaluate neoepitopes?",{"text":117,"@type":113},"Experimentally validated neoepitopes were obtained from NEPdb, and NetMHCPan4.1 was used to analyze IC50 values and differential agretopicity.",{"name":119,"@type":110,"acceptedAnswer":120},"How many candidate KRAS CD8+ neoepitopes were identified?",{"text":121,"@type":113},"The study identified 21 candidate KRAS CD8+ neoepitopes, with recommended candidates showing TCR-facing mutated residues, notable differential agretopicity, and higher binding affinity than wild-type.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369913,1790248726,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","RESEARCH ARTICLE  \nEditorial Process: Submission:11/06/2024 Acceptance:07/10/2025  \nIntegrative Computational Immunology Applied to Identify and Characterize CD8+ T-cell Neoepitopes of Shared KRAS Neoantigen Oncogenic Driver Hotspot Mutations  \nLeana Rich Herrera-Ong*  \nAbstract  \nBackground: Lung, pancreatic, and colorectal cancers continue to rank among the most lethal malignancies. Despite the availability of advanced treatments, these cancer types demand more effective immunotherapeutic solutions. Neoantigen formation is a common feature of cancer mechanisms, with the Kirsten rat sarcoma viral oncogene homolog (KRAS) being the most frequently mutated oncogene in various cancers. This study employed immunoinformatic tools and databases to identify and analyze potential cytotoxic T-cell neoepitopes derived from KRAS hotspot mutations. Methods: Experimentally validated neoepitopes were obtained from NEPdb. Key parameters such as IC50 values, differential agretopicity, mutation positions, and immunogenicity of the neoepitopes were determined. Results from this analysis, combined with additional factors recommended in the literature, were used to identify and characterize potential KRAS neoepitopes. Sequences with G12A, G12C, G12D, G12S, G12V, G12R, G13D, andA59T mutations were prepared. IC50 values and differential agretopicity were analyzed using NetMHCPan4.1. The epitopes’safety profilesand population coverage were assessed, and the top recommended neoepitopes were docked to calculate the dissociation constant (KD) and Gibbs free energy of binding (ΔGbind) . Results: Twenty-one candidate KRAS CD8+ neoepitopes were identified. The recommended neoepitopes (KLVVVGAAGV, LVVVGAAGV, LVVVGACGV, KLVVVGADGV, LVVVGADGV, KLVVVGASGV, KLVVVGAV, KLVVVGAVGV, LVVVGAVGV, and VVGAVGVGK) exhibit TCRfacing mutated residues, significant differential agretopicity, and higher binding affinity compared to their wild-type counterparts. Safety and population coverage analyses suggest that these candidate KRAS neoepitopes are unlikely to cause allergy, toxicity, or cross-reactivity, and they demonstrate coverage across a substantial proportion of the population. Conclusion: This study introduced a preliminary integrative workflow for neoepitope identification. Findings indicate that the 21 candidate KRAS neoepitopes have the potential to be recognized by cytotoxic lymphocytes and trigger immune response. This positions them as promising elements for anti-cancer vaccine formulations, pending successful in vitro, animal, and clinical studies.  \nKeywords: KRAS-neoepitope-lung cancer-pancreatic cancer-colorectal cancer  \nAsian Pac J Cancer Prev, 26 (7), 2413-2423  \nIntroduction  \nCancer ranks as the second leading cause of mortality worldwide, with lung cancer accounting for the majority of these deaths, making it the deadliest form of the disease. Other highly fatal cancers include colorectal and pancreatic cancer [1]. Despite advancements in treatments like surgery, radiation, passive immunotherapy, and chemotherapy, the global 5-year survival rates for lung (10-20%), pancreatic (12%), and colorectal (64-65%) cancer patients remain alarmingly low [2, 3, 4] .  \nCancers often generate neoantigens, which can include over 10 tumor-specific somatic mutations per megabase (Mb) [5] . These neoantigens, also known as tumor-specific antigens (TSA), arise from somatic DNA  \nmutations, viral open reading frame (ORF) integrations, altered RNA splicing mechanisms, and disrupted posttranslational modifications. Since neoantigens are unique to cancer cells, they serve as ideal targets for immunotherapy. Among oncogenes, the Kirsten rat sarcoma viral oncogene homolog (KRAS) has the highest mutation rate across all cancer types. As a member of the RAS family of GTPases, KRAS hydrolyzes guanosine triphosphate (GTP) into guanosine diphosphate (GDP) . Other RAS family members include Harvey rat sarcoma viral oncogene (HRAS) and neuroblastoma rat sarcoma viral oncogene (NRA","cbCailzw3dE3UJlR","https://ap.wps.com/l/cbCailzw3dE3UJlR","pdf",906551,11,"English","# Abstract\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Cancer prevalence and neoantigens\n## Role of KRAS and hotspot mutations","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To identify and characterize potential cytotoxic CD8+ T-cell neoepitopes generated from shared KRAS neoantigen oncogenic driver hotspot mutations.\"},{\"question\":\"Which database and tools were used to evaluate neoepitopes?\",\"answer\":\"Experimentally validated neoepitopes were obtained from NEPdb, and NetMHCPan4.1 was used to analyze IC50 values and differential agretopicity.\"},{\"question\":\"How many candidate KRAS CD8+ neoepitopes were identified?\",\"answer\":\"The study identified 21 candidate KRAS CD8+ neoepitopes, with recommended candidates showing TCR-facing mutated residues, notable differential agretopicity, and higher binding affinity than wild-type.\"}]","Integrative Computational Immunology Applied to Identify and Characterize CD8+ T-cell Neoepitopes of Shared KRAS Neoantigen Oncogenic Driver Hotspot Mutations | PDF",1790185192,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/143f218f4675c0425e01bdd60fda1138.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d38314e1cb6d7526593b85fa001da39.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4734c3067ba006bae1e48fb4026b7b3d.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f902013d0661a3b0390fa3ca702925d.webp",980,1385]